To investigate the radioimmunotherapeutic efficacy, radio-immunoconjugate 131-I-3G9, 811-I-3H11 and 131-I-NMIgG (irre levant antibody) were i.p. injected into nude mice bearing human gastric cancer xenograftes. Each a...To investigate the radioimmunotherapeutic efficacy, radio-immunoconjugate 131-I-3G9, 811-I-3H11 and 131-I-NMIgG (irre levant antibody) were i.p. injected into nude mice bearing human gastric cancer xenograftes. Each animal received a single doses of 555MBq. Over 14 days the accumulative absorbed doses in tumors were 13.7 Gy for 131-I-3H11 and 12.17 Gy for 131-I-3G9. Both were significantly higher than that for 131-I-NMIgG (3.23 Gy). Thera peutic efficacy appeared most sharply from 2 to 3 weeks after injection. The inhibition ratio of tumor were 86% and 70% for 131-I-3H11 and 131-I-3G9 respectively. Histopathological evidance indicated that in tumor tissues radioactive damage was showed as karyopyknosis, karyorrhexis and necrosis or partial disappearance of tumor cells, while in the other tissues no radioactive damage was observed. WBC counts of all animals did not show significant difference before and after treatment, which indicated that the haemopoietic function of bone marrow was not affected.展开更多
Three hybridized cell line. F- 19. N-35 and SIA-2 which secrete monoclonal antibodies (McAbs) against human lung cancer have been established by using the cell fusion technique. The three cell lines have been cultured...Three hybridized cell line. F- 19. N-35 and SIA-2 which secrete monoclonal antibodies (McAbs) against human lung cancer have been established by using the cell fusion technique. The three cell lines have been cultured in vitro for 14 to 16 months and can produce Monoclonal Antibodies steadily. With the three monoclonal antibodies, the immunohistochemistry technique has been applied to detect different histocytes from human lung cancer, various normal or abnormal tissues and organs. The potency that the monoclonal antibodies will be applied in clinic has also been studied.展开更多
文摘To investigate the radioimmunotherapeutic efficacy, radio-immunoconjugate 131-I-3G9, 811-I-3H11 and 131-I-NMIgG (irre levant antibody) were i.p. injected into nude mice bearing human gastric cancer xenograftes. Each animal received a single doses of 555MBq. Over 14 days the accumulative absorbed doses in tumors were 13.7 Gy for 131-I-3H11 and 12.17 Gy for 131-I-3G9. Both were significantly higher than that for 131-I-NMIgG (3.23 Gy). Thera peutic efficacy appeared most sharply from 2 to 3 weeks after injection. The inhibition ratio of tumor were 86% and 70% for 131-I-3H11 and 131-I-3G9 respectively. Histopathological evidance indicated that in tumor tissues radioactive damage was showed as karyopyknosis, karyorrhexis and necrosis or partial disappearance of tumor cells, while in the other tissues no radioactive damage was observed. WBC counts of all animals did not show significant difference before and after treatment, which indicated that the haemopoietic function of bone marrow was not affected.
文摘Three hybridized cell line. F- 19. N-35 and SIA-2 which secrete monoclonal antibodies (McAbs) against human lung cancer have been established by using the cell fusion technique. The three cell lines have been cultured in vitro for 14 to 16 months and can produce Monoclonal Antibodies steadily. With the three monoclonal antibodies, the immunohistochemistry technique has been applied to detect different histocytes from human lung cancer, various normal or abnormal tissues and organs. The potency that the monoclonal antibodies will be applied in clinic has also been studied.
